Author

Ozlem Kucuk

Institution: Ankara University

Observed institution: Ankara University

OpenAlex ID: A5124201724

68 Ga-PSMA-11 PET/CT for Initial Staging of Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Predicts Overall Survival: An IAEA Multicenter Study

2026 · Juliano J. Cerci, Stefano Fanti, et al. · Journal of Nuclear Medicine · 4

ProTACT: A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [ 225 Ac]Ac-FL-020, a PSMA-targeted radioconjugate, in patients with mCRPC.

2026 · Robert Dreicer, Giuseppe Cardaci, et al. · Journal of Clinical Oncology

ProTACT: Preliminary data from a first-in-human, phase 1 study evaluating the safety, tolerability, and anti-tumor activity of [ 225 Ac]Ac-FL-020, a PSMA-targeted radioconjugate, in patients with mCRPC.

2026 · Alison Yan Zhang, Giuseppe Cardaci, et al. · Journal of Clinical Oncology

ProTACT: A first-in-human, phase 1 study evaluating the safety, tolerability, and anti-tumor activity of [ 225 Ac]Ac-FL-020, an anti-PSMA radioconjugate in patients with mCRPC.

2026 · Giuseppe Cardaci, Aviral Singh, et al. · Journal of Clinical Oncology

ProTACT: A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [ 225 Ac]Ac-FL-020, an anti-PSMA radioconjugate in patients with mCRPC.

2026 · Giuseppe Cardaci, Aviral Singh, et al. · Journal of Clinical Oncology

Works count: 5

Citation count: 4

H-index: 1

I10-index: